RSV vaccine could cut baby hospital admissions by more than 80%, study suggests
- A study has shown that a jab called nirsevimab can provide immediate protection against chest infections in babies, resulting in an 83% reduction in RSV-related hospital admissions. The jab is being considered for a UK rollout and has been approved but not yet available on the NHS.
- The study included 8,058 babies, with those who received the jab having a significantly lower number of hospital admissions compared to those who received standard treatment. The efficacy of the jab was found to be 83.2%.
- The jab, which is a monoclonal antibody, could alleviate the burden on the NHS and protect thousands of babies from hospitalization. It is being considered for a future national RSV immunization program in the UK.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left2Leaning Right3Center2Last UpdatedBias Distribution43% Right
Bias Distribution
- 43% of the sources lean Right
43% Right
L 29%
C 28%
R 43%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage